Bristol-Myers Squibb Co (BMY)
56.22
-2.28
(-3.90%)
USD |
NYSE |
Nov 15, 16:00
56.17
-0.05
(-0.09%)
Pre-Market: 20:00
Bristol-Myers Squibb Research and Development Expense (TTM): 10.45B for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 10.45B |
| June 30, 2024 | 10.31B |
| March 31, 2024 | 9.673B |
| December 31, 2023 | 9.299B |
| September 30, 2023 | 9.331B |
| June 30, 2023 | 9.507B |
| March 31, 2023 | 9.57B |
| December 31, 2022 | 9.509B |
| September 30, 2022 | 9.517B |
| June 30, 2022 | 10.08B |
| March 31, 2022 | 10.24B |
| December 31, 2021 | 10.20B |
| September 30, 2021 | 11.43B |
| June 30, 2021 | 10.95B |
| March 31, 2021 | 10.99B |
| December 31, 2020 | 11.14B |
| September 30, 2020 | 9.49B |
| June 30, 2020 | 8.369B |
| March 31, 2020 | 7.172B |
| December 31, 2019 | 6.148B |
| September 30, 2019 | 5.418B |
| June 30, 2019 | 5.32B |
| March 31, 2019 | 6.43B |
| December 31, 2018 | 6.332B |
| September 30, 2018 | 6.89B |
| Date | Value |
|---|---|
| June 30, 2018 | 7.171B |
| March 31, 2018 | 6.415B |
| December 31, 2017 | 6.468B |
| September 30, 2017 | 6.015B |
| June 30, 2017 | 5.592B |
| March 31, 2017 | 5.179B |
| December 31, 2016 | 5.012B |
| September 30, 2016 | 5.456B |
| June 30, 2016 | 5.45B |
| March 31, 2016 | 6.04B |
| December 31, 2015 | 5.92B |
| September 30, 2015 | 5.193B |
| June 30, 2015 | 5.044B |
| March 31, 2015 | 4.604B |
| December 31, 2014 | 4.534B |
| September 30, 2014 | 4.302B |
| June 30, 2014 | 4.212B |
| March 31, 2014 | 3.747B |
| December 31, 2013 | 3.731B |
| September 30, 2013 | 3.856B |
| June 30, 2013 | 3.914B |
| March 31, 2013 | 3.925B |
| December 31, 2012 | 3.904B |
| September 30, 2012 | 3.83B |
| June 30, 2012 | 3.852B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
6.148B
Minimum
Dec 2019
11.43B
Maximum
Sep 2021
9.668B
Average
9.622B
Median
Research and Development Expense (TTM) Benchmarks
| Johnson & Johnson | 16.41B |
| Eli Lilly and Co | 10.53B |
| Merck & Co Inc | 22.98B |
| Pfizer Inc | 10.60B |
| AbbVie Inc | 8.722B |